ATE411077T1 - Zusammensetzungen, welche gastrin/cck- rezeptorligande und egf-rezeptorligande enthalten,zur induzierung der neogenese von inselzellen - Google Patents

Zusammensetzungen, welche gastrin/cck- rezeptorligande und egf-rezeptorligande enthalten,zur induzierung der neogenese von inselzellen

Info

Publication number
ATE411077T1
ATE411077T1 AT02708990T AT02708990T ATE411077T1 AT E411077 T1 ATE411077 T1 AT E411077T1 AT 02708990 T AT02708990 T AT 02708990T AT 02708990 T AT02708990 T AT 02708990T AT E411077 T1 ATE411077 T1 AT E411077T1
Authority
AT
Austria
Prior art keywords
receptor ligand
inducing
compositions containing
treatment
gastrin
Prior art date
Application number
AT02708990T
Other languages
English (en)
Inventor
Stephen Brand
Original Assignee
Waratah Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waratah Pharmaceuticals Inc filed Critical Waratah Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE411077T1 publication Critical patent/ATE411077T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
AT02708990T 2001-01-12 2002-01-11 Zusammensetzungen, welche gastrin/cck- rezeptorligande und egf-rezeptorligande enthalten,zur induzierung der neogenese von inselzellen ATE411077T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26163801P 2001-01-12 2001-01-12

Publications (1)

Publication Number Publication Date
ATE411077T1 true ATE411077T1 (de) 2008-10-15

Family

ID=22994183

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02708990T ATE411077T1 (de) 2001-01-12 2002-01-11 Zusammensetzungen, welche gastrin/cck- rezeptorligande und egf-rezeptorligande enthalten,zur induzierung der neogenese von inselzellen

Country Status (13)

Country Link
US (2) US6992060B2 (de)
EP (1) EP1351742B1 (de)
JP (1) JP2004520345A (de)
KR (1) KR20040064605A (de)
CN (1) CN1486204A (de)
AT (1) ATE411077T1 (de)
AU (1) AU2002243501B2 (de)
CA (1) CA2434330A1 (de)
DE (1) DE60229352D1 (de)
ES (1) ES2315350T3 (de)
IL (1) IL156828A0 (de)
WO (1) WO2002055152A2 (de)
ZA (1) ZA200305347B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
US20060014684A1 (en) * 2000-03-03 2006-01-19 University Technologies International Inc. Novel uses of EGF
WO2002055152A2 (en) * 2001-01-12 2002-07-18 Waratah Pharmaceuticals, Inc. Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands
WO2003018782A2 (en) 2001-08-30 2003-03-06 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
CA2460184A1 (en) 2001-09-14 2003-03-27 Stem Cell Therapeutics Inc. Prolactin induced increase in neural stem cell numbers and therapeutical use thereof
US20030054551A1 (en) * 2001-09-18 2003-03-20 Stem Cell Therapeutics Inc. Effect of growth hormone and IGF-1 on neural stem cells
US7037504B2 (en) * 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
EP1441754A1 (de) * 2001-10-26 2004-08-04 University Technologies International Inc. Verwendung von egf zur behandlung von pathogeninfektionen des urogenitalstraktes
US20060234373A1 (en) * 2002-05-24 2006-10-19 Alex Rabinovitch Treatment for diabetes
CN100448483C (zh) * 2002-05-24 2009-01-07 瓦拉塔药品公司 糖尿病的治疗
KR20050048542A (ko) * 2002-06-07 2005-05-24 와라타 파마수티컬즈, 인크. 당뇨병의 치료를 위한 조성물 및 방법
EP1837031B1 (de) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Methoden und Kompositionen um Diabetes zu behandeln
EP1546198A1 (de) * 2002-07-31 2005-06-29 Stem Cell Therapeutics Inc. Verfahren zur verbesserung der proliferation, der differenzierung und des berlebens von neuralen stammzellen unter verwendung von pituitary adenylate cyclase activating polypeptide (pacap)
KR20050074492A (ko) * 2002-10-22 2005-07-18 와라타 파마수티컬즈, 인크. 당뇨병의 치료
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
US20060009516A1 (en) * 2002-10-24 2006-01-12 Mcgill University Use of ingap for reversing diabetes
MXPA05012605A (es) * 2003-05-27 2006-02-22 Waratah Pharmaceuticals Inc Composiciones que comprenden compuestos de gastrina y sus usos en la diabetes.
US20080039379A1 (en) * 2003-05-27 2008-02-14 Waratah Pharmaceuticals, Inc. Compositions Comprising Gastrin Compounds and Their Use in Diabetes
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
US20090202494A1 (en) * 2004-01-30 2009-08-13 Antonio Cruz Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
ES2392282T3 (es) * 2004-02-13 2012-12-07 Stem Cell Therapeutics Corp. Uso de la hormona luteinizante (LH) y de la gonadotropina coriónica (hCG) para la proliferación de células precursoras neurales y la neurogénesis
WO2006002532A1 (en) * 2004-07-01 2006-01-12 Waratah Pharmaceuticals, Inc. Methods and compositions using cd3 agonists
AU2005291810B2 (en) 2004-10-07 2011-12-08 Stem Cell Therapeutics Corp. Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds
EP1928488A4 (de) 2005-09-27 2009-07-22 Stem Cell Therapeutics Corp Regulierung der oligodendrozyten-vorläufer-zellproliferation mit prolactin
JP2009510134A (ja) * 2005-10-07 2009-03-12 ワラタ ファーマシューティカルズ， インコーポレイテッド Ｄｐｐ−ｉｖ阻害剤およびガストリン化合物の組み合わせ使用
CA2632550C (en) * 2005-12-15 2017-07-25 Nestec S.A. Medium chain triglycerides for preserving cognitive function
WO2007076371A2 (en) 2005-12-19 2007-07-05 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
EP2004212A4 (de) * 2006-03-17 2010-07-14 Stem Cell Therapeutics Corp Kontinuierliche dosierschemata für neuralstammzellen-proliferierende mittel und neuralstammzellen-differenzierende mittel
WO2008007933A1 (en) * 2006-07-14 2008-01-17 Postech Academy-Industry Foundation Epidermal growth factor increasing insulin secretion and lowering blood glucose
WO2008106775A1 (en) * 2007-03-02 2008-09-12 Waratah Pharmaceuticals Inc. Combination treatment for diabetes using an egf receptor ligand and a gastrin compound
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
JP5799397B2 (ja) 2008-06-12 2015-10-28 イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ 癌の抑制
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
WO2011131646A1 (en) * 2010-04-20 2011-10-27 Novo Nordisk A/S Long-acting gastrin derivatives
KR102027750B1 (ko) * 2018-05-03 2019-10-02 연세대학교 산학협력단 당 배출용 조성물
WO2021002645A1 (ko) * 2019-07-01 2021-01-07 연세대학교 산학협력단 하이드로겔 및 egfr 리간드를 유효성분으로 포함하는 당 배출용 조성물
KR102109385B1 (ko) * 2019-08-21 2020-05-12 연세대학교 산학협력단 당 배출용 조성물

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE38892B1 (en) * 1973-03-28 1978-06-21 Ici Ltd Pharmaceutical compositions
JPS6028994A (ja) * 1983-07-08 1985-02-14 Wakunaga Seiyaku Kk 〔２１―ロイシン〕ヒトウロガストロン
GB8409961D0 (en) 1984-04-17 1984-05-31 Searle & Co Pharmaceutical compositions
US4686283A (en) * 1985-04-16 1987-08-11 Syntex (U.S.A.) Inc. Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis
US5102789A (en) 1989-03-15 1992-04-07 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of epideramal growth factor in pichia pastoris yeast cells
US5158935A (en) 1989-05-12 1992-10-27 Chiron Corporation Human epidermal growth factor having substitution at position 11
IE68593B1 (en) * 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
US5434135A (en) 1990-08-02 1995-07-18 Indu Parikh Growth factor compositions, preparation and use
AU2489992A (en) 1991-08-16 1993-03-16 Chiron Corporation Muteins of epidermal growth factor exhibiting enhanced binding at low ph
US6558952B1 (en) 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
US5885956A (en) * 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
EP1132091A1 (de) 1994-01-24 2001-09-12 The General Hospital Corporation Behandlung von Diabetes
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US20040037818A1 (en) 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
AU2153500A (en) 1998-11-19 2000-06-05 Millennium Pharmaceuticals, Inc. Egf-like nucleic acids and polypeptides and uses thereof
AU780794B2 (en) * 1999-02-10 2005-04-14 Es Cell International Pte Ltd Pancreatic progenitor cells, methods and uses related thereto
US6610535B1 (en) 2000-02-10 2003-08-26 Es Cell International Pte Ltd. Progenitor cells and methods and uses related thereto
WO2002055152A2 (en) * 2001-01-12 2002-07-18 Waratah Pharmaceuticals, Inc. Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands
WO2002079457A1 (en) * 2001-03-29 2002-10-10 Ixion Biotechnology, Inc. Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway
US7037504B2 (en) 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
US20060234373A1 (en) 2002-05-24 2006-10-19 Alex Rabinovitch Treatment for diabetes
EP1837031B1 (de) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Methoden und Kompositionen um Diabetes zu behandeln
KR20050048542A (ko) 2002-06-07 2005-05-24 와라타 파마수티컬즈, 인크. 당뇨병의 치료를 위한 조성물 및 방법
KR20050074492A (ko) 2002-10-22 2005-07-18 와라타 파마수티컬즈, 인크. 당뇨병의 치료
US20040229810A1 (en) 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
ES2307932T3 (es) 2003-04-28 2008-12-01 Pirelli Tyre S.P.A. Neumatico que incluye una banda de rodadura con varias capas y su metodo de fabricacion.
MXPA05012605A (es) 2003-05-27 2006-02-22 Waratah Pharmaceuticals Inc Composiciones que comprenden compuestos de gastrina y sus usos en la diabetes.
US20090202494A1 (en) 2004-01-30 2009-08-13 Antonio Cruz Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
WO2006002532A1 (en) 2004-07-01 2006-01-12 Waratah Pharmaceuticals, Inc. Methods and compositions using cd3 agonists
JP2009510134A (ja) 2005-10-07 2009-03-12 ワラタ ファーマシューティカルズ， インコーポレイテッド Ｄｐｐ−ｉｖ阻害剤およびガストリン化合物の組み合わせ使用
WO2007062531A1 (en) 2005-12-02 2007-06-07 Waratah Pharmaceuticals, Inc. Combination treatments with gastrin agonists for diabetes and related diseases
WO2007095737A1 (en) 2006-02-21 2007-08-30 Waratah Pharmaceuticals Inc. Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound

Also Published As

Publication number Publication date
DE60229352D1 (de) 2008-11-27
US6992060B2 (en) 2006-01-31
CN1486204A (zh) 2004-03-31
AU2002243501B2 (en) 2007-11-22
JP2004520345A (ja) 2004-07-08
US20060234932A1 (en) 2006-10-19
US7476388B2 (en) 2009-01-13
ES2315350T3 (es) 2009-04-01
EP1351742B1 (de) 2008-10-15
WO2002055152A9 (en) 2003-01-23
IL156828A0 (en) 2004-02-08
US20020098178A1 (en) 2002-07-25
ZA200305347B (en) 2004-10-11
KR20040064605A (ko) 2004-07-19
WO2002055152A2 (en) 2002-07-18
CA2434330A1 (en) 2002-07-18
EP1351742A2 (de) 2003-10-15
WO2002055152A8 (en) 2002-11-14
WO2002055152A3 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
ATE411077T1 (de) Zusammensetzungen, welche gastrin/cck- rezeptorligande und egf-rezeptorligande enthalten,zur induzierung der neogenese von inselzellen
ATE375166T1 (de) Zusammensetzungen und verfahren zur behandlung von diabetes
DE60326002D1 (de) Behandlung von diabetes.
ZA9811241B (en) New piperidinyl-substituted pyridylalkane alkene and alkine carboxamides
ATE457166T1 (de) Orale zusammensetzungen zur behandlung von diabetes
TR200001892T2 (tr) Monomer cinsi ensülin analogları ve bunların kullanımı.
ATE314046T1 (de) Mittel zum oxidativen färben von keratinfasern, welche ein kationisches polyvinyllactam enthalten
BRPI0408229A (pt) preparação farmacêutica, métodos para preparar um ligando de ligação de zinco, para prolongar a ação de uma preparação de insulina estabilizada por ácido e para tratar diabete do tipo 1 ou tipo 2, e, uso de uma preparação
SG143042A1 (en) Treatment for diabetes
UY26483A1 (es) Activadores de la glucoquinasa transolefinica
BR9913284A (pt) Métodos para administrar peptìdeos insulinotrópicos
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
WO2002099052A3 (en) Opns as modifiers of the p53 pathway and methods of use
PT1112275E (pt) Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
DE59000024D1 (de) Verwendung von rheniumorganischen verbindungen zur oxidation von c-c-mehrfachbindungen, darauf basierende oxidationsverfahren und neue rheniumorganische verbindungen.
WO2002053106A3 (en) Autoantigen composition
DK0467026T3 (da) Middel til farvning af hår og anvendelse af midlet
DE820303T1 (de) p277 PEPTIDANALOGE, PHARMAZEUTISCHE ZUSAMMENSTELLUNG DAVON ZUR BEHANDLUNG UND DIAGNOSE VON DIABETES
EE03771B1 (et) Tetrahüdropüridoühendid, neid sisaldav ravim ja nende kasutamine
PT988302E (pt) Benzonaftiridinas
DE69817774D1 (de) Trägerstoff für trockenpulverinhalator, verfahren zu dessen herstellung und diesen enthaltende arzneimittel
DE69319337D1 (en) Polyetheramidoamine hydrogele als heparinersatz
DE69817991D1 (de) Medizinisches gerät
DE69802884T2 (de) Zusammensetzung zum oxidativen Färben von Keratinfasern, die als Oxidationsbase ein Aminosäurederivat enthält, und neue Aminosäurederivate.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties